Today, March 31, marks World Colorectal Cancer Day, an occasion to raise awareness about one of the most common cancers…
Josep Tabernero
This year, Vall d’Hebron Barcelona Hospital Campus commemorated World Cancer Day with a public talk at Palau Robert, coinciding with…
The BREAKWATER open-label, randomized phase 3 study was designed to evaluate first-line treatment with targeted therapies encorafenib and cetuximab plus…
The results of the international phase 3 MATTERHORN clinical trial show that adding the antibody durvalumab, an immune checkpoint inhibitor,…
Results from the MATTERHORN phase 3 study demonstrate that immunotherapy in combination with standard chemotherapy before and after surgery significantly…
The BREAKWATER open-label, randomized phase 3 study was designed to evaluate first-line treatment with targeted therapies encorafenib and cetuximab plus…
The American Association for Cancer Research (AACR) has officially announced this year’s class of Fellows of the AACR Academy. The…
Published in the journal Nature Communications*, results from a first-in-human, phase I clinical trial of an oral, potent and reversible…
Presented today at the ASCO Gastrointestinal Cancers Symposium, 23-25 January in San Francisco, results of 2 phase 3 clinical studies…
Clarivate™ has revealed the annual list of Highly Cited Researchers™ 2024, curated by its experts at the Institute for Scientific…
